Familial Hypercholesterolemia and Atherosclerosis in Cloned Minipigs Created by DNA Transposition of a Human PCSK9 Gain-of-Function Mutant

被引:152
|
作者
Al-Mashhadi, Rozh H. [1 ,2 ]
Sorensen, Charlotte B. [3 ]
Kragh, Peter M. [4 ]
Christoffersen, Christina [5 ]
Mortensen, Martin B. [1 ,2 ]
Tolbod, Lars P. [6 ,7 ]
Thim, Troels [1 ,2 ]
Du, Yutao [4 ]
Li, Juan [4 ]
Liu, Ying [4 ]
Moldt, Brian [3 ]
Schmidt, Mette [8 ]
Vajta, Gabor [4 ,9 ]
Larsen, Torben [4 ]
Purup, Stig [4 ]
Bolund, Lars [3 ,10 ]
Nielsen, Lars B. [5 ,11 ]
Callesen, Henrik [4 ]
Falk, Erling [1 ,2 ]
Mikkelsen, Jacob Giehm [3 ]
Bentzon, Jacob F. [1 ,2 ]
机构
[1] Aarhus Univ, Aarhus Univ Hosp, Dept Cardiol, DK-8200 Aarhus, Denmark
[2] Aarhus Univ, Dept Clin Med, DK-8200 Aarhus N, Denmark
[3] Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark
[4] Aarhus Univ, Dept Anim Sci, DK-8830 Tjele, Denmark
[5] Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark
[6] Aarhus Univ Hosp, Dept Nucl Med, DK-8200 Aarhus N, Denmark
[7] Aarhus Univ Hosp, PET Ctr, DK-8200 Aarhus N, Denmark
[8] Univ Copenhagen, Dept Large Anim Sci, DK-1870 Frederiksberg C, Denmark
[9] Cent Queensland Univ, Rockhampton, Qld 4702, Australia
[10] Beishan Ind Zone, BGI Shenzhen, BGI HuaDa JiYin, Shenzhen 518083, Peoples R China
[11] Univ Copenhagen, Dept Biomed Sci, DK-2200 Copenhagen N, Denmark
关键词
POSITRON-EMISSION-TOMOGRAPHY; SLEEPING-BEAUTY TRANSPOSASE; CORONARY ATHEROSCLEROSIS; PLAQUE INFLAMMATION; MAMMALIAN-CELLS; BINDING DOMAIN; DEFICIENT MICE; DISEASE; EXPRESSION; LESIONS;
D O I
10.1126/scitranslmed.3004853
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Lack of animal models with human-like size and pathology hampers translational research in atherosclerosis. Mouse models are missing central features of human atherosclerosis and are too small for intravascular procedures and imaging. Modeling the disease in minipigs may overcome these limitations, but it has proven difficult to induce rapid atherosclerosis in normal pigs by high-fat feeding alone, and genetically modified models similar to those created in mice are not available. D374Y gain-of-function mutations in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene cause severe autosomal dominant hypercholesterolemia and accelerates atherosclerosis in humans. Using Sleeping Beauty DNA transposition and cloning by somatic cell nuclear transfer, we created Yucatan minipigs with liver-specific expression of human D374Y-PCSK9. D374Y-PCSK9 transgenic pigs displayed reduced hepatic low-density lipoprotein (LDL) receptor levels, impaired LDL clearance, severe hypercholesterolemia, and spontaneous development of progressive atherosclerotic lesions that could be visualized by noninvasive imaging. This model should prove useful for several types of translational research in atherosclerosis.
引用
收藏
页数:10
相关论文
共 45 条
  • [21] CANDIDATES FOR MONOCLONAL ANTIBODIES TO PCSK9, AMONG HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN THE DYSLIPIDEMIA REGISTRY OF THE SPANISH ATHEROSCLEROSIS SOCIETY
    Perez-Calahorra, Sofia
    Plana, Nuria
    Sanchez-Hernandez, Rosa Ma
    Marco-Benedi, Victoria
    Brea, Angel
    Suarez, Manuel
    Mauri, Marta
    Villa, Alexander
    Martorell, Esperanza
    Lahoz, Carlos
    ATHEROSCLEROSIS, 2017, 263 : E41 - E42
  • [22] Pharmacodynamics of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With PCSK9 Gain-Of-Function or ApoB Loss-Of-Function Mutations: An Open-Label Extension Study
    Krempf, Michel
    Hopkins, Paul N.
    Bruckert, Eric
    Luc, Gerald
    Lee, Shane
    Donahue, Stephen
    CIRCULATION, 2018, 138
  • [23] Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia A case report
    Bayona, Ane
    Arrieta, Francisco
    Rodriguez-Jimenez, Carmen
    Cerrato, Francisco
    Rodriguez-Novoa, Sonia
    Fernandez-Lucas, Milagros
    Gomez-Coronado, Diego
    Mata, Pedro
    MEDICINE, 2020, 99 (34)
  • [24] Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding
    Sarkar, Samantha K.
    Matyas, Angela
    Asikhia, Ikhuosho
    Hu, Zhenkun
    Golder, Mia
    Beehler, Kaitlyn
    Kosenko, Tanja
    Lagace, Thomas A.
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [25] CLINICAL CHARACTERISTICS OF COMMON PCSK9 GAIN-OF-FUNCTION E32K VARIANT WITH HIGHER TG ELEVATION, AND DOUBLE HETEROZYGOTES WITH COMMON PCSK9 VARIANTS AND LDLR MUTATIONS
    Nohara, A.
    Kawashiri, M. A.
    Tada, H.
    Yoshida, M.
    Mori, M.
    Nakanishi, C.
    Yagi, K.
    Inazu, A.
    Yamagishi, M.
    Mabuchi, H.
    ATHEROSCLEROSIS, 2016, 252 : E35 - E35
  • [26] PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expression
    Cui, Yuan feng
    Chen, Xiao cui
    Mijiti, Tuoluonayi
    Abudurusuli, Abidan
    Deng, Li hui
    Ma, Xiang
    Chen, Bangdang
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [27] PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia
    Kaya, Esra
    Kayikcioglu, Meral
    Vardarli, Asli Tetik
    Eroglu, Zuhal
    Payzin, Serdar
    Can, Levent
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2017, 18 (04): : 266 - 272
  • [28] Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 MiceBrief Report
    Lu, Hong
    Howatt, Deborah A.
    Balakrishnan, Anju
    Graham, Mark J.
    Mullick, Adam E.
    Daugherty, Alan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (09) : 1753 - 1757
  • [29] Ossabaw Pigs With a PCSK9 Gain-of-Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model for Preclinical Studies
    Yuan, Fang
    Guo, Liang
    Park, Kyoung-Ha
    Woollard, John R.
    Taek-Geun, Kwon
    Jiang, Kai
    Melkamu, Tamene
    Zang, Bin
    Smith, Samantha L.
    Fahrenkrug, Scott C.
    Kolodgie, Frank D.
    Lerman, Amir
    Virmani, Renu
    Lerman, Lilach O.
    Carlson, Daniel F.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (06):
  • [30] Initial clinical Experience with the PCSK9 Inhibitors Evolocumab and Alirozumab for LDL and Lp (a) Reduction in Patients with familial Hypercholesterolemia or manifest Atherosclerosis-Progression
    Poudel, Madan Raj
    Stoyanova, Dana
    Gottfried, Regine
    Horstkotte, Dieter
    Van Buuren, Frank
    Mellwig, Klaus-Peter
    INTERNIST, 2018, 59 : S65 - S66